Dialysis solution having at least one osmotic agent

US11090388B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11090388-B2
Application numberUS-201615775956-A
CountryUS
Kind codeB2
Filing dateNov 14, 2016
Priority dateNov 13, 2015
Publication dateAug 17, 2021
Grant dateAug 17, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to a dialysis solution having at least one osmotic agent, with the osmotic agent being a polysaccharide modified by 2-sulfoethyl groups.

First claim

Opening claim text (preview).

The invention claimed is: 1. A dialysis solution having at least one osmotic agent, characterized in that the osmotic agent is a modified polysaccharide, wherein the modified polysaccharide is a 2-sulfoethyl starch, characterized in that the starch underlying the 2-sulfoethyl starch is a starch that was reduced with NaBH 4 before the sulfoethylation, and wherein the molar mass of the unmodified sulfoethyl starch is between 1,000 and 20,000 g/mol. 2. A dialysis solution in accordance with claim 1 , characterized in that the modified polysaccharide has a degree of substitution between 0.05 and 1.0. 3. A dialysis solution in accordance with claim 1 , characterized in that the dialysis solution does not contain any further osmotic agent in addition to the modified polysaccharide. 4. A dialysis solution in accordance with claim 1 , characterized in that the dialysis solution furthermore has electrolytes and a buffer system. 5. A dialysis solution in accordance with claim 4 , characterized in that the electrolytes are selected from the group consisting of sodium ions, potassium ions, calcium ions, magnesium ions, chloride ions, and combinations thereof. 6. A dialysis solution in accordance with claim 4 , characterized in that the buffer system is a lactate buffer, a hydrogen carbonate buffer, or a combination thereof. 7. A dialysis solution in accordance with claim 4 , characterized in that the electrolytes, where present and independently of one another, are present in the following concentrations in the dialysis solution (figures in mmol/l): Sodium ions 125-150 Potassium ions   0-4.5 Calcium ions   0-2.5 Magnesium ions 0-5 Chloride ions  90-120 Lactate/Lactic acid/(Hydrogen) carbonate/CO 2 30-60. 8. A dialysis solution in accordance with claim 1 , characterized in that the pH of the dialysis solution is between 5.0 and 8.0. 9. A dialysis solution in accordance with claim 1 for use in peritoneal dialysis. 10. A dialysis solution in accordance with claim 1 , characterized in that the modified polysaccharide has a degree of substitution between 0.2 and 0.5. 11. A dialysis solution in accordance with claim 1 , characterized in that the dialysis solution comprises mixtures of the modified polysaccharide and further osmotic agents. 12. A dialysis solution in accordance with claim 1 , characterized in that the dialysis solution comprises mixtures of the modified polysaccharide and (i) carnitine or (ii) taurine. 13. A dialysis solution in accordance with claim 1 , characterized in that the pH of the dialysis solution is between 5.5 and 6.5. 14. A dialysis solution in accordance with claim 1 , characterized in that the pH of the dialysis solution is between 6.5 and 7.5. 15. A method of preparing an osmotic agent of a dialysis solution in accordance with claim 1 comprising modification of a polysaccharide starch by 2-sulfoethyl groups.

Assignees

Inventors

Classifications

  • A61K47/36Primary

    Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title

  • Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine · CPC title

  • Starch or degraded starch, e.g. amylose, amylopectin · CPC title

  • Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean) · CPC title

  • Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11090388B2 cover?
The invention relates to a dialysis solution having at least one osmotic agent, with the osmotic agent being a polysaccharide modified by 2-sulfoethyl groups.
Who is the assignee on this patent?
Fresenius Medical Care Deutschland Gmbh, Univ Jena Friedrich Schiller
What technology area does this patent fall under?
Primary CPC classification A61K47/36. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).